We are live on ! Find out more
DFTX

Definium Therapeutics

159 hedge funds and large institutions have $53.6M invested in Definium Therapeutics in 2022 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 33 increasing their positions, 41 reducing their positions, and 48 closing their positions.

New
Increased
Maintained
Reduced
Closed

180% more call options, than puts

Call options by funds: $4.31M | Put options by funds: $1.54M

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0.06% less ownership

Funds ownership: 0.82%0.76% (-0.06%)

10% less funds holding

Funds holding: 176159 (-17)

20% less repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 41

26% less capital invested

Capital invested by funds: $72.4M → $53.6M (-$18.9M)

33% less first-time investments, than exits

New positions opened: 32 | Existing positions closed: 48

Holders
159
Holders Change
-17
Holders Change %
-9.66%
% of All Funds
2.51%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
32
Increased
33
Reduced
41
Closed
48
Calls
$4.31M
Puts
$1.54M
Net Calls
+$2.77M
Net Calls Change
-$81K

DFTX Hedge Fund Activity: Q1 2022 in Review

159 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Definium Therapeutics (DFTX) for Q1 2022, worth a combined $53.6M — down 26% from $72.4M a quarter earlier.

Sellers outnumbered buyers: 48 funds closed out of DFTX and 32 opened new positions — a net loss of 16 holders — while 41 trimmed existing stakes and 33 added.

The largest buyer was State Street, adding an estimated $482K. The largest seller was Millennium Management, cutting an estimated $740K.

  • 159 institutional investors held Definium Therapeutics (DFTX) as of Q1 2022, down from 176 in Q4 2021.
  • Funds reported $53.6M of Definium Therapeutics stock for Q1 2022, down 26% quarter-over-quarter.
  • 32 funds opened new Definium Therapeutics positions in Q1 2022 and 48 closed out, a net change of -16 holders.
  • The largest Definium Therapeutics buyer in Q1 2022 was State Street, an estimated $482K added.
  • The largest Definium Therapeutics seller in Q1 2022 was Millennium Management, an estimated $740K sold.

Based on aggregated 13F filings for Q1 2022.